ReviewNutrients2022
Human Milk Oligosaccharides as Potential Antibiofilm Agents: A Review.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Gut microbiota alterations in Neonatal Intensive Care Unit extremely preterm infants: a Chinese tertiary center study.Translational pediatrics · 2026Article
- Human Milk Oligosaccharides: Shaping the Anti-Infective Status in Infancy.Microorganisms · 2026Review
- The impact of human milk oligosaccharides and galacto-oligosaccharides on the growth of early life pathogenic gut bacteria.Frontiers in microbiology · 2026Article
- Article
- Seal milk oligosaccharides rival human milk complexity and exhibit functional dynamics during lactation.Nature communications · 2025Article
- Anti-Pneumococcal Properties of the Native Human Milk Oligosaccharide Fraction: A Concentration-Dependent Study.International journal of molecular sciences · 2025Article
- Recent advances of 3-fucosyllactose in health effects and production.Archives of microbiology · 2024Review
- Impact of Human Milk Oligosaccharides and Probiotics on Gut Microbiome and Mood in Autism: A Case Report.Microorganisms · 2024Article
- Assessment of 2'-Fucosyllactose and Lacto-N-Neotetraose Solution as an Irrigant inClinics and practice · 2024Article
- Recent Advances in the Microbial Production of Human Milk Oligosaccharides.Current opinion in food science · 2024Article
- Interactions of human milk oligosaccharides with the immune system.Frontiers in immunology · 2024Review
- Prebiotics in New-Born and Children's Health.Microorganisms · 2023Review
- Determinants of microbial colonization in the premature gut.Molecular medicine (Cambridge, Mass.) · 2023Review
- Gut Microbial Sialidases and Their Role in the Metabolism of Human Milk Sialylated Glycans.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Surface-associated bacterial communities called biofilms are ubiquitous in nature. Biofilms are detrimental in medical settings due to their high tolerance to antibiotics and may alter the final pathophysiological outcome of many healthcare-related infections. Several innovative prophylactic and therapeutic strategies targeting specific mechanisms and/or pathways have been discovered and exploited in the clinic. One such emerging and original approach to dealing with biofilms is the use of human milk oligosaccharides (HMOs), which are the third most abundant solid component in human milk after lactose and lipids. HMOs are safe to consume (GRAS status) and act as prebiotics by inducing the growth and colonization of gut microbiota, in addition to strengthening the intestinal epithelial barrier, thereby protecting from pathogens. Moreover, HMOs can disrupt biofilm formation and inhibit the growth of specific microbes. In the present review, we summarize the potential of HMOs as antibacterial and antibiofilm agents and, hence, propose further investigations on using HMOs for new-age therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.